Muehling Olaf M, Wilke Norbert M, Panse Prasad, Jerosch-Herold Michael, Wilson Betsy V, Wilson Robert F, Miller Leslie W
Section of Cardiovascular MRI of the Department of Diagnostic Radiology, University of Minnesota Medical School Minneapolis, Minneapolis, Minnesota, USA.
J Am Coll Cardiol. 2003 Sep 17;42(6):1054-60. doi: 10.1016/s0735-1097(03)00924-0.
The goal of this study was to detect transplant arteriopathy (Tx-CHD) by a reduced myocardial perfusion reserve (MPR) and resting endomyocardial/epimyocardial perfusion ratio (Endo/Epi ratio).
Transplant arteriopathy often lacks clinical symptoms and is the reason for frequent surveillance angiography in heart transplant (Tx) recipients. Magnetic resonance perfusion imaging (MRPI) allows noninvasive assessment of transmural and selective endomyocardial and epimyocardial perfusion.
Fifteen healthy volunteers (controls) and three groups (A, B, C) of Tx recipients were included. In controls and patients, MPR (hyperemic/resting perfusion) and Endo/Epi ratio were determined with MRPI after injection of gadolinium-diethylenetriamine pentaacetic acid at rest and during hyperemia (intravenous adenosine). Group A (n = 10) had no left ventricular (LV) hypertrophy and/or prior rejection, while patients in group B (n = 10) had at least one of these characteristics. Patients in group A and B had a normal coronary angiogram and a coronary flow reserve (CFR) of > or =2.5 (CFR = hyperemic/resting blood flow). Group C (n = 7) had Tx-CHD diagnosed by angiography and a reduced CFR (<2.5).
In group C, MPR (1.7 +/- 0.5) and Endo/Epi ratio (1.1 +/- 0.2) were significantly reduced compared with controls (4.2 +/- 0.7 and 1.6 +/- 0.3; both p < 0.0001), group A (3.6 +/- 0.7 and 1.6 +/- 0.2; both p < 0.0001) and B (2.7 +/- 0.9, p < 0.01 and 1.4 +/- 0.1, p < 0.04). Transplant arteriopathy can be excluded by an MPR of >2.3 with sensitivity and specificity of 100% and 85%. If LV hypertrophy and prior rejection are excluded, Tx-CHD can be excluded by an Endo/Epi ratio of >1.3 with 100% and 80%.
Magnetic resonance perfusion imaging detects Tx-CHD by a decreased MPR. After exclusion of LV hypertrophy and prior rejection, resting Endo/Epi ratio alone might be sufficient to indicate Tx-CHD.
本研究的目的是通过降低的心肌灌注储备(MPR)和静息心内膜/心外膜灌注比值(Endo/Epi比值)来检测移植后冠心病(Tx-CHD)。
移植后冠心病通常缺乏临床症状,是心脏移植(Tx)受者频繁进行血管造影监测的原因。磁共振灌注成像(MRPI)可对心肌全层及选择性的心内膜和心外膜灌注进行无创评估。
纳入15名健康志愿者(对照组)和三组Tx受者(A组、B组、C组)。在对照组和患者中,静息及充血状态下(静脉注射腺苷)注射钆喷酸葡胺后,通过MRPI测定MPR(充血/静息灌注)和Endo/Epi比值。A组(n = 10)无左心室(LV)肥厚和/或既往排斥反应,而B组(n = 10)患者至少具有其中一项特征。A组和B组患者冠状动脉造影正常,冠状动脉血流储备(CFR)≥2.5(CFR = 充血/静息血流)。C组(n = 7)经血管造影诊断为Tx-CHD且CFR降低(<2.5)。
与对照组(4.2±0.7和1.6±0.3;均p < 0.0001)、A组(3.6±0.7和1.6±0.2;均p < 0.0001)和B组(2.7±0.9,p < 0.01和1.4±0.1,p < 0.04)相比,C组的MPR(1.7±0.5)和Endo/Epi比值(1.1±0.2)显著降低。MPR>2.3可排除移植后冠心病,其敏感性和特异性分别为100%和85%。如果排除LV肥厚和既往排斥反应,Endo/Epi比值>1.3可排除Tx-CHD,敏感性和特异性分别为100%和80%。
磁共振灌注成像通过降低的MPR检测Tx-CHD。排除LV肥厚和既往排斥反应后,仅静息Endo/Epi比值可能足以提示Tx-CHD。